Strensiq Inj (asfotase alfa, AstraZeneca), which was subject to prior review by the Health Insurance Review and Assessment Service since it was listed for reimbursement in June 2020, will be converted and be subject to post-review from next month.

The drug is a long-term enzyme replacement therapy used to treat bone symptoms in patients with perinatal- and infantile-onset hypophosphatasia and was a drug that previously required prior review from HIRA before administration for coverage.

However, starting this month, its reimbursed use will no longer require prior review, expanding access to treatment.

HIRA has announced the revisions to the “Detailed Matters on the Procedu